Tender For supply of Allopathic Drugs For The Year 2025-27 (Addendum Items As Per Corrigendum ) Allopathic Drugs For The Year 2025-27 (Addendum Items As Per Corrigendum ) , Tab Stavudine (30Mg), Lamivudine (150Mg) And Nevirapine (200Mg) , Tab. Lamivudine 150Mg , Tab. Sofosbuvir 400Mg. , Tab. Tenoofovir 300Mg+Lamivudine 300Mg , Tab. Stavudine + Lamivudine (30Mg+150Mg) , Tab.Zidovudine +Lamivudine+Nevirapine (300Mg+150Mg+200Mg) , Tab. Amitriptyline 75Mg , Tab. Diazepam 5Mg. , Tab. Diclofenac Sodium 50 Mg , Tab. Diltiazem 30 Mg , Inj. Etoposide 20Mg/Ml, 5Ml Vial , Inj. Adenosine 6Mg/2Ml , 2Ml Intravenous Infusion Vial/Amp. , Inj. Alprostadil Ip 500Mcg/Ml, Amp , Inj. Esmolol 10Mg/Ml, Each 10Ml Vial , Inj. Isoprenaline Hydrochloride Ip 2Mg/Ml, 1Ml Amp , Inj. Phenobarbitone Ip 200 Mg/Ml, 1Ml Amp , Inj. Sodium Nitroprusside 50Mg, Per 2Ml Vial , Inj. Vecuronium Bromide Ip 10Mg (1Mg/Ml) Lyophilized With Water For Injection (Composite Pack Containing Drug And Wfi). Particulars Of Wfi Including Batch No. Date Of Manufacture, Date Of Expiry Manufacturer Etc. Must Be Mentioned On Secondary And Tertiary Packing. Nabl Report Of The Wfi Supplied With Main Item Must Also Be Supplied With The Supplies , Inj. Vecuronium Bromide Ip 4Mg, 4Mg Vial , Tab. Gefitinib Ip 250Mg , Inj. Diclofenac Sodium 75Mg/Ml, Iv Bolus (1Ml Amp) , Atropine Sulphate Eye Ointment 1% W/W, 5Gm, Each 5Gm Tube , Cap.Nifedipine 5Mg , Tab. Chloroquine 500Mg , Biphasic Insulin Aspart 100U/Ml (Mixture Of Insulin Aspart (30%) + Insulin Aspart Protamine (70%), 3Ml Penfill , Inj. Somatropin Biosynthetic-R-Dna Origin (Hgh), Pfs, 10Mg/1.5Ml , Per Pfs , Inj. Somatropin Biosynthetic-R-Dna Origin (Hgh), Pfs, 15Mg/1.5Ml , Per Pfs , Insulin Aspart 100U/Ml, 3Ml Penfill , Recombinant Third Generation Factor Viii (250 Iu) As Per Wfh Standard Guidelines, Vial , Recombinant Third Generation Factor Viii (500 Iu) As Per Wfh Standard Guidelines, Vial , Tab. Morphine 10Mg , Inj. Lorazipam 4Mg/Ml, Per Vial
